Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs

#NICE #NICEFAD #NICEfinaldraftguidance #Alzheimerstreatments #NHS #donanemab #Kisunla #EliLilly #lecanemab #Leqembi #Eisai #negativedraftrecommendations #mildcognitiveimpairment #milddementia #Alzheimersdisease #NHSresources #NICEassessments #cognitiveimpairment
www.nice.org.uk/news/article...